LMAT Stock Analysis: Buy, Sell, or Hold?

LMAT - LeMaitre Vascular, Inc.

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
$108.49
-0.26 (-0.24%) ▼
5d: -1.67%
30d: +1.95%
90d: +33.77%
BUY
MODERATE Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 07, 2026

Get Alerted When LMAT Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading chart...

Loading historical data...

💡
Bottom Line:
💡 BUY OPPORTUNITY: LMAT shows positive signals but monitor for confirmation. Market pricing in 0.5% annual growth which appears achievable. Moderate conviction.

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

0% (Stagnation) 50% (Hyper Growth)
EST. PRICE IN 2031
$110.52
Based on 6.8% avg growth
INTRINSIC VALUE TODAY
$68.63
Trading above fair value

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.

In-depth Analysis How we analyze

Valuation Analysis: LMAT is currently trading at $108.49, which is considered fair relative to its 30-day fair value range of $101.28 to $112.58. The stock's valuation (Forward PE: 34.1) is in line with its historical norms (33.6). At these levels, the market is pricing in 0.5% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.

Technical Outlook: Technically, LMAT is in a strong uptrend. Immediate support is located at $104.00, while resistance sits at $113.59.

Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (8th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.

Quick Decision Summary

Current Position FAIR
Fair Price Range $101.28 - $112.58
Company Quality Score 57/100 (HOLD)
Options IV Signal 8th percentile (COMPLACENCY WARNING)
Volume Confirmation HIGH
Confidence Score 74.6%

All Signals

  • NEUTRAL: Price in fair range
  • BULLISH: Options cheap (IV 8th percentile)
  • NEUTRAL: Mixed technical signals (55/100)
  • BULLISH: High volume confirmation
  • NEUTRAL: Near Wall St target ($111.22)
  • NEUTRAL: Market pricing in 0.5% annual earnings growth - fairly valued

Fair Price Analysis

30-Day Fair Range $101.28 - $112.58
Current vs Fair Value FAIR
Expected Move (7 Days) ±$4.23 (3.9%)

Support & Resistance Levels

Support Level $104.00
Resistance Level $113.60
Current Trend Strong Uptrend
Technical data as of Apr 2, 2026

Fundamental Context

Forward P/E (Next Year Est.) 34.07
Wall Street Target $111.22 (+2.5%)
Revenue Growth (YoY) 15.7%
Earnings Growth (YoY) 41.4%
Profit Margin 23.1%
Valuation Premium vs History +0.5% premium
PE vs Historical 34.1 vs 33.6 FAIR
Market-Implied Price Targets If current PE multiple persists
Implied Growth (YoY): +0.5% (market-implied from PE analysis)
1-Year Target $109.03 (+1%)
2-Year Target $109.58 (+1%)
3-Year Target $110.13 (+2%)
3-Yr Target (if PE normalizes) (PE: 34→34) PE COMPRESSION $108.61 (+0%)
Earnings growth offset by PE compression
3-Year Scenarios Using analyst projected EPS growth
Bull: (PE: 34.1, Growth: 9.6%) $142.99 (+32%)
Base: (SPY PE: 20.6, Growth: 9.6%) $86.33 (-20%)
Bear: (PE: 17.5, Growth: 9.6%) $73.38 (-32%)
📈 Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (42x PE), but valuation improves significantly next year (34x PE) as earnings recover.
Trailing PE: 42.19 | Current EPS (TTM): $2.52
Bull Case $146.52 (+36%)
Analyst growth 25.3%, PE expands to 46.4
Base Case $133.20 (+24%)
Market implied 25.3%, PE stable at 42.2
Bear Case $72.29 (-33%)
Severe decline -20.0%, PE contracts to 35.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit
bloggers & journalists: you are free to use our charts with attribution.
Last updated: April 02, 2026 6:27 PM ET
Data refreshes hourly during market hours. Next update: 7:27 PM
🔥 Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
George W Lemaitre SELL 55930 shares 2026-03-02
David B Roberts SELL 8464 shares 2026-02-27
Trent G Kamke SELL 1044 shares 2026-02-27

Unlock Insider Activity

See real-time buying/selling by company executives for LMAT.

Create Free Account

Already have an account? Log In

Top Rated Medical Instruments & Supplies Stocks

Top-rated stocks in Medical Instruments & Supplies by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
ISRG
Intuitive Surgical Inc
BUY
33 analysts
$607 58 HOLD
ALC
Alcon AG
STRONG BUY
27 analysts
$94 61 BUY
RGEN
Repligen Corporation
STRONG BUY
19 analysts
$186 60 BUY
WST
West Pharmaceutical Serv…
STRONG BUY
13 analysts
$318 61 BUY
AVTR
Avantor Inc
HOLD
21 analysts
$11 65 BUY

Advanced LMAT Option Strategies

Professional options setups generated by AI based on today's LMAT price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for LMAT

LMAT Technical Chart LMAT Price Prediction LMAT Earnings Date LMAT Investment Advisor LMAT Fair Price Analyzer LMAT Options Advisor LMAT Options Chain LMAT Options Analysis LMAT Competitors
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals